Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

December 31, 2015

Conditions
CancerInfluenza Viral Infections
Interventions
BIOLOGICAL

Standard Trivalent Influenza Vaccine

Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.

BIOLOGICAL

High-Dose Influenza Vaccine

Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.

Trial Locations (2)

14621

Rochester General Hospital, Rochester

14625

Lipson Cancer Center Linden Oaks Medical Campus, Rochester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Saad Jamshed MD

OTHER

NCT01666782 - Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy | Biotech Hunter | Biotech Hunter